Hemostatic treatment using factor VIII concentrates for neutralizing high-responding inhibitors prior to CVAD insertion for immune-tolerance induction therapy

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 1, 2012, Pages 66-71

  Shibata, Masaru ^a   Nakagawa, Takashi ^a   Akioka, Shinji ^b   Giddings, John C ^c   Kanehiro, Hiromichi ^a   Matsumoto, Tomoko ^a   Ogiwara, Kenichi ^a   Yada, Koji ^a   Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

^b Saiseikai Kyoto Hospital   (Japan)

^c CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

cost effectiveness; CVAD; hemophilia; high dose factor VIII; inhibitor

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

ALGORITHM; ARTHROPATHY; ARTICLE; BLEEDING; CASE REPORT; CENTRAL VENOUS CATHETER; CHILD; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MEGADOSE; HEMATOCRIT; HEMOPHILIA A; HEMOPHILIC ARTHROPATHY; HEMOSTASIS; HUMAN; IMMUNOLOGICAL TOLERANCE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT RESPONSE;

BLOOD COAGULATION FACTOR INHIBITORS; CHILD; CHILD, PRESCHOOL; FACTOR VIII; HEMOPHILIA A; HEMOSTATICS; HUMANS; INFANT; MALE;

EID: 84857541432     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611412364     Document Type: Article

References (15)

1. Hoyer LW, Scandella D. Factor VIII inhibitors: structure and function in autoantibody and haemophilia A patients. Semin Hematol. 1994 ; 31 (2 suppl 4). 1-5
2. Kempton CL, White GC.. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood. 2009 ; 113 (1). 11-17
3. Kulkarni R, Aledort LM, Berntorp E, et al. Therapeutic choices for patients with hemophilia and high-titer inhibitors. Am J Hematol. 2001 ; 67 (4). 240-246
4. Komvilaisak P, Connolly B, Naqvi A, et al. Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders. Haemophilia. 2006 ; 12 (Suppl 6). 87-93
5. Hardisty RM. MacPherson JC. A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma. Thromb Diath Haemorrh. 1962 ; 7: 215-228
6. Kasper CK, Aledort L, Counts RB, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975 ; 34: 869-871
7. Yoshioka A, Nishio K, Shima M. Thrombelastogram as a haemostatic monitor during recombinant factor VIIa treatment in hemophilia A patients with inhibitor to factor VIII. Haemostasis. 1996 ; 26 Suppl 1: 139-142
8. Dargaud Y, Lienhart A, Meunier S, et al. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia. 2005 ; 11 (5). 552-558
9. Hayashi T, Tanaka I, Shima M, et al. Unresponsiveness to factor VIII inhibitor bypassing agents during haemostatic treatment for life-threatening massive bleeding in a patient with haemophilia A and a high responding inhibitor. Haemophilia. 2004 ; 10 (4). 397-400
10. Kipps TJ. Human B cell biology. Int Rev Immunol. 1997 ; 15 (3-4). 243-264
11. Kasper CK Progress in Hemostasis and Thrombosis. 9 th ed. Philadelphia, PA: Saunders; 1989;57-86. Coller BS, ed. Philadelphia, PA: Saunders ; 1989: 57-86.
12. Van Leeuwen EF, Mauser-Bunschoten EP, Van Dijken PJ, et al. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose. Br J Haematol. 1986 ; 64 (2). 291-297
13. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001 ; 40 (11). 815-832
14. Teitel J. Inhibitor economics. Semin Hematol. 2006 ; 43 (2 Suppl 4). S14 - S17
15. Hay CR, Brown S, Collins PW, et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol. 2006 ; 133 (6). 591-605